CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.

MLA

Castillo, Jorge J., et al. “CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenström Macroglobulinemia Treated with Proteasome Inhibitors.” American Journal of Hematology, vol. 95, no. 4, Apr. 2020, pp. E95–98. EBSCOhost, https://doi.org/10.1002/ajh.25730.

APA

Castillo, J. J., Gustine, J. N., Meid, K., Flynn, C. A., Demos, M. G., Guerrera, M. L., Jimenez, C., Kofides, A., Liu, X., Munshi, M., Tsakmaklis, N., Patterson, C. J., Xu, L., Yang, G., Hunter, Z. R., & Treon, S. P. (2020). CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 95(4), E95–E98. https://doi.org/10.1002/ajh.25730

Chicago

Castillo, Jorge J, Joshua N Gustine, Kirsten Meid, Catherine A Flynn, Maria G Demos, Maria L Guerrera, Cristina Jimenez, et al. 2020. “CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenström Macroglobulinemia Treated with Proteasome Inhibitors.” American Journal of Hematology 95 (4): E95–98. doi:10.1002/ajh.25730.